| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $38,568,817 ) (Continued on the next page) |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 000 | 4 | NIH | 6/11/2026 | $8,164,281 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA300144 | Acetylation modulates T cell receptor signaling | 000 | 1 | NIH | 6/3/2026 | $498,582 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1NS142343 | Enhanced PINK1 kinase activity as a therapeutic strategy against alpha-synuclein pathology and neurodegeneration | 000 | 1 | NIH | 5/22/2026 | $1,875,783 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS144153 | Length, methylation, and purity of expanded C9orf72 repeat across diseases, tissues, and cell populations | 000 | 1 | NIH | 5/22/2026 | $627,408 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS140081 | Multi-omic signatures of ALS-spectrum disorders | 000 | 1 | NIH | 5/22/2026 | $622,792 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS136022 | Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (SEA-NOBI-ALS) | 001 | 3 | NIH | 7/22/2026 | $5,728,540 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R13CA290996 | Science of Community Outreach and Engagement (SoCOE) Conference | 000 | 3 | NIH | 7/14/2026 | $10,000 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 000 | 4 | NIH | 7/7/2026 | $657,515 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 001 | 3 | NIH | 3/25/2026 | $576 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 3 | NIH | 1/16/2026 | $49,738 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 001 | 5 | NIH | 2/23/2026 | $299,525 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 000 | 5 | NIH | 12/18/2025 | $2,695,731 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA276313 | A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer | 000 | 4 | NIH | 7/7/2026 | $635,464 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG084236 | ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System | 000 | 4 | NIH | 6/25/2026 | $993,414 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K23DK131338 | Approaches and Outcomes of Shared Decision-making and Patient Centered Care Delivery in Barrett's Esophagus | 000 | 5 | NIH | 6/8/2026 | $199,654 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsin-like serine proteases | 002 | 5 | NIH | 6/23/2026 | $326,840 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK139207 | Deciphering Pancreatitis Microenvironment through Intravital Imaging | 000 | 3 | NIH | 4/8/2026 | $578,659 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R37CA248298 | Role of Sirt2 in T Cell Metabolism | 000 | 7 | NIH | 3/19/2026 | $357,994 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA295558 | Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor | 001 | 2 | NIH | 4/27/2026 | $59,970 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA295558 | Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor | 000 | 2 | NIH | 12/18/2025 | $539,735 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 000 | 4 | NIH | 3/3/2026 | $578,941 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA288808 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6 | 001 | 2 | NIH | 4/16/2026 | $18,290 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA288808 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6 | 000 | 2 | NIH | 12/30/2025 | $164,619 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 002 | 2 | NIH | 7/15/2026 | -$1,055,614 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 001 | 2 | NIH | 3/5/2026 | $113,854 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 000 | 2 | NIH | 12/17/2025 | $1,024,684 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA296671 | ECT2 Isoform Switch in Pancreatic Cancer. | 000 | 2 | NIH | 12/16/2025 | $164,619 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA296671 | ECT2 Isoform Switch in Pancreatic Cancer. | 001 | 2 | NIH | 4/16/2026 | $18,290 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 001 | 4 | NIH | 2/24/2026 | $70,955 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 000 | 4 | NIH | 12/15/2025 | $638,607 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK139604 | Protein Kinase D1 as a switch from acute to chronic pancreatitis | 000 | 3 | NIH | 5/5/2026 | $340,388 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K23HL183845 | Breast Cancer Survivors with Obesity – Semaglutide’s Impact on Preclinical Markers of Cardiovascular Disease | 000 | 1 | NIH | 7/3/2026 | $199,244 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA305145 | Local Delivery of Chemotherapy to Aggressive Meningiomas using a Bioresorbable Implant | 000 | 1 | NIH | 6/23/2026 | $620,671 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F32NS146048 | Decoding and Targeting the Molecular Mechanisms of TRAF7/KLF4 Driver Mutations in Meningioma | 001 | 1 | NIH | 4/15/2026 | $1,260 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F32NS146048 | Decoding and Targeting the Molecular Mechanisms of TRAF7/KLF4 Driver Mutations in Meningioma | 000 | 1 | NIH | 2/24/2026 | $80,020 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS142134 | Harnessing Neurosurgery to Empower GBM-Targeted CAR-T Immunotherapies Uniquely Designed to Combat the Tumor Microenvironment” | 000 | 1 | NIH | 7/10/2026 | $599,699 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA304198 | Senescence and Resistance in Glioblastoma | 000 | 1 | NIH | 7/10/2026 | $687,314 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG081203 | Neuronal ABCA7 loss of function and Alzheimer’s disease | 000 | 2 | NIH | 6/19/2026 | $686,761 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35GM162590 | Hypolipoprotein Phenotyping and Evaluation of Sepsis | 000 | 1 | NIH | 7/21/2026 | $462,410 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS147997 | Plaque morphologic characteristics that affect prevention of stroke by carotid revascularization | 000 | 1 | NIH | 5/14/2026 | $442,086 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS123052 | C9orf72-mediated features transcriptomic signatures and translational studies for frontotemporal dementia and related disorders | 000 | 3 | NIH | 6/26/2026 | $528,338 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F31NS141239 | Role of meningeal lymphatic drainage in CSF1R-related leukoencephalopathy | 002 | 1 | NIH | 4/15/2026 | $576 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F31NS141239 | Role of meningeal lymphatic drainage in CSF1R-related leukoencephalopathy | 001 | 1 | NIH | 1/15/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F31NS141239 | Role of meningeal lymphatic drainage in CSF1R-related leukoencephalopathy | 000 | 1 | NIH | 1/15/2026 | $49,538 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG087165 | Elucidating the Pathomechanisms of APOE4 in Lewy Body Dementia | 000 | 3 | NIH | 3/9/2026 | $777,126 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | UG3AI190113 | Antibiotic Allergy: Phenotypes, Endotypes, and Mechanisms | 003 | 3 | NIH | 6/23/2026 | $322,792 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA262393 | Targeted Prevention of Postpartum-Related Breast Cancer (PRBC) | 001 | 5 | NIH | 4/29/2026 | $42,289 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA262393 | Targeted Prevention of Postpartum-Related Breast Cancer (PRBC) | 000 | 5 | NIH | 1/16/2026 | $380,600 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK117910 | Mechanisms of Hereditary Pancreatitis | 000 | 7 | NIH | 2/25/2026 | $690,067 |
|
